IL22 and neoplasm: So far, Th22 cells and their main signature, cytokine IL-22, have been associated with tumor progression in patients with hepatocellular carcinoma [148], colon cancer [149], lung cancer [150,151], gastric cancer [152], and ovarian cancer [153], among others.